Aug 8, 2014 | Coding, Billing, and Collections, Laboratory Management and Operations, Laboratory News, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement, Management & Operations
Pathologists should take note that an increasing number of patients who want genetic tests are complaining when they learn their insurance plan will not pay for such tests
Concerned about the increased cost of genetic tests, health insurers are becoming reluctant to pay for many types of molecular diagnostics and gene tests. As they do, however, they face a buzzsaw of angry patients—many of whom see a genetic test as their last resort for a diagnosis and selection of a therapy that might just work for them.
Reuters recently reported that health insurance companies are reluctant to pay providers for gene-sequencing tests until more research becomes available. This is a sign for pathologists and clinical laboratory managers that enough patients have been affected by this to justify news coverage by a major news source.
(more…)
Jun 27, 2014 | Coding, Billing, and Collections, Laboratory Management and Operations, Laboratory News, Laboratory Pathology, Management & Operations
Even this premier academic center is experiencing a reduced volume of inpatient discharges, signaling to pathologists that efforts to keep people out of hospitals are succeeding
What does it mean when a prominent healthcare system like Partners HealthCare of Boston, Massachusetts, reports a decline in revenue and operating profit? After all, as one of the nation’s premier academic health centers, it is reasonable to expect that it would enjoy strong demand for its inpatient and outpatient services.
That is why pathologists and clinical laboratory managers will find it interesting that Partners experienced a decline in patient volumes during its second quarter ending March 31, 2014. Similar to other hospitals throughout the nation, fewer inpatients are showing up at hospitals operated by Partners HealthCare. (more…)
Feb 21, 2014 | Digital Pathology, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Sales and Marketing, Management & Operations
This price includes all costs except overhead, but without a high volume of customers, Illumina’s $10-million price for the HiSeq X Ten machine may not be a wise investment
Competition continues to be fierce in the race to the $1,000 whole human genome. Most recently, Illumina announced the availability of its latest gene sequencing system, along with the claim that it can deliver a whole human genome at a cost of just $1,000. But, as most pathologists know, the devil is in the details, since not every Illumina customer is likely to achieve that price point.
When Illumina, a San Diego-based technology company, announced its new HiSeq X Ten genetic-sequencing machine in December, 2013, Illumina CEO Jay T. Flatley claimed the company’s system can deliver “full-coverage human genome sequences for less than $1,000,” down from $500 million 10 years ago. The new system is expected to ship in the first quarter of 2014.
(more…)
Feb 5, 2014 | Digital Pathology, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology
Partners HealthCare and Geisinger Health are among health systems making investments and developing the clinical utility of genome sequencing
Next-generation gene sequencing is making fast inroads among the nation’s largest academic centers and health systems. This is an auspicious development for the clinical laboratory industry. It positions pathologists to play a greater role in clinical care and genetic medicine.
News accounts and published research suggest that mega systems—including Partners HealthCare, Geisinger Health System, Scripps Health, and Medical College of Wisconsin—are among first movers investing in genome-sequencing equipment and assembling the medical expertise necessary to establish genetic-testing programs and help physicians utilize gene sequences where appropriate for patient care. (more…)
Dec 16, 2013 | Compliance, Legal, and Malpractice, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement, Management & Operations
Across the nation, as many as 500 ACOs are organizing or already delivering clinical services to as many as 43 million Americans
There is no better way to track the progress of accountable care organizations (ACOs) than to monitor a list of the largest ACOs in the United States. Many pathologists and clinical laboratory managers already serve patients who are enrolled in ACOs.
Oliver Wyman, a consulting firm headquartered in New York City, is tracking the development of ACOs in different regions of the nation. It recently published the statistics on the number of ACOs and estimated ACO enrollment.
(more…)
